If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
447.00    -2.50 (-0.56%)
Bid:
447.00
Ask:
454.00
Spread: 7.00 (1.566%)
Market Cap: £219.84m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Trading Update and Interim Management Statement

23 Oct 2013 07:00

RNS Number : 1453R
Zotefoams PLC
23 October 2013
 



23 October 2013

 

 

Zotefoams plc

("Zotefoams" or "the Company")

 

Trading Update and Interim Management Statement for the Quarter ended 30 September 2013

 

Zotefoams plc (the "Company"), a world leader in cellular material technology, today announces a trading update and its interim management statement for the third quarter ended 30 September 2013.

Growth in sales of High-Performance Products ("HPP") products and Azote® polyolefin foams in Asia in the third quarter has been offset by an unexpected shortfall in shipments to some European polyolefin customers, leaving total sales in the quarter at the same level as 2012 and below the level previously anticipated. These falls are, in the main, related to larger customers who are responding to continued destocking in the downstream market, which affects their demand levels in the short-term. The Board considers it prudent to assume that this trend will continue for the remainder of the year but, with the benefit of our shorter lead times, we expect to progress in this market in 2014.

Our HPP products business continues to grow strongly with long-term projects giving positive momentum into 2014 and beyond.

MuCell Extrusion, our technology licensing business, is focusing increasingly on consumer packaging. Given the scale of this opportunity further investment in our technology is being made during the fourth quarter.

Foreign currency rates have been less favourable in the third quarter compared to the first half of 2013 and the adverse impact in this period, mainly due to our US-dollar denominated investments, is in the region of £0.4 million.

The overall impact of these factors is that the Company expects second half profit to be below the level seen in the first half and therefore profit for the year to be below previous management expectations.

Although it is disappointing to see the current shortfall in European polyolefin foams, the Board considers the impact to be short-term and is encouraged by the performance of the business elsewhere. A return to growth is expected in 2014, and the Board remains confident in the long-term prospects for the business.

 

 

Enquiries:

Zotefoams plc

0208-664-1600

David Stirling, Managing Director

Clifford Hurst, Finance Director

FTI Consulting

0207-831-3113

John Dineen, Victoria Foster Mitchell

 

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular material technology. Using a unique manufacturing process with environmentally friendly nitrogen expansion, Zotefoams produces lightweight foams in Croydon, UK and Kentucky, USA for diverse markets worldwide through its global sales force. Zotefoams also owns and licenses patented MuCell® microcellular foam technology from a base in Massachusetts, USA to customers worldwide and sells T-Tubes® advanced insulation systems made from its patented ZOTEK® fluoropolymer foams.

 

www.zotefoams.com

 

ZOTEK®, Azote® and microZOTE® are registered trademarks of Zotefoams plc. MuCell® is a registered trademark of Trexel Inc. T-Tubes® is a registered trademark of UFP Technologies Inc.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCMTBRTMBBTBJJ
Date   Source Headline
11th Aug 20094:19 pmRNSHolding(s) in Company
10th Aug 200912:45 pmRNSHolding(s) in Company
4th Aug 20097:00 amRNSHalf Yearly Report
20th Jul 20091:42 pmRNSHolding(s) in Company
3rd Jul 20097:00 amRNSTrading Statement
17th Jun 20095:33 pmRNSHolding(s) in Company
5th Jun 200912:23 pmRNSDirector/PDMR Shareholding
19th May 200910:30 amRNSAnnual Information Update
12th May 200910:30 amRNSVoting Rights and Capital
7th May 20097:00 amRNSAGM Statement
7th Apr 200910:51 amRNSNotice of AGM
26th Mar 20097:00 amRNSAdditional Listing
18th Mar 20091:50 pmRNSDirector/PDMR Shareholding
16th Mar 20095:19 pmRNSDirector/PDMR Shareholding
10th Mar 20097:00 amRNSFinal Results
22nd Jan 200911:36 amRNSHolding(s) in Company
5th Jan 20091:19 pmRNSVoting Rights and Capital
19th Dec 20087:00 amRNSTrading Statement
12th Dec 200811:04 amRNSDirector/PDMR Shareholding
11th Dec 20082:20 pmRNSHolding(s) in Company
3rd Nov 20087:00 amRNSInterim Management Statement
30th Oct 20082:25 pmRNSAdditional Listing
14th Aug 20087:00 amRNSDirector/PDMR Shareholding
5th Aug 20087:00 amRNSInterim Results
9th Jul 20089:11 amRNSAcquires Stake
1st Jul 20087:00 amRNSTrading Update
5th Jun 20089:37 amRNSVoting rights and capital
23rd May 20085:38 pmRNSAnnual Information Update
8th May 20087:01 amRNSAGM Statement
14th Apr 20087:00 amRNSBlocklisting Interim Review
8th Apr 20086:07 pmRNSAdditional Listing
8th Apr 20088:18 amRNSNotice of AGM
25th Mar 20082:46 pmRNSDirector/PDMR Shareholding
4th Mar 20087:01 amRNSFinal Results
3rd Mar 20087:00 amRNSCustomer Achievement
1st Feb 20081:46 pmRNSTotal Voting Rights
21st Dec 20072:48 pmRNSDirectors' Shareholdings
26th Nov 200710:04 amRNSAdditional Listing
12th Nov 20077:01 amRNSDirector/PDMR Shareholding
7th Nov 20078:45 amRNSDirectors' Shareholdings
30th Oct 20072:55 pmRNSHolding in Company
19th Oct 20077:01 amRNSProduct Achievement
17th Oct 20079:32 amRNSBlocklisting Interim Review
5th Sep 200712:29 pmRNSHolding(s) in Company
28th Aug 20077:02 amRNSMarketing Alliance
7th Aug 20077:00 amRNSInterim Results
30th Jul 20074:45 pmRNSVoting rights & capital
12th Jul 20074:02 pmRNSDirectorate Change
29th Jun 200711:04 amRNSTrading Update
28th Jun 20072:23 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.